IGI Laboratories, Inc. Announces First ANDA Approval

 IGI Laboratories, Inc., a New Jersey based generic topical pharmaceutical company, has announced that it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The FDA has approved IGI’s application for lidocaine hydrochloride USP 4% topical solution. Lidocaine …

Read the source article at ca.finance.yahoo.com

About the Author

Leave a Reply